CALIXAR, a French biotech company, and the Germans Trias i Pujol Research Institute (IGTP), a public Spanish research center, have entered into a research collaboration. IGTP is a public research institute founded in 1995. Their main fields of research are cancer and infectious diseases, endocrine and metabolism or cardiovascular diseases and possessed several high technology facilities included cryobiology, translational genomics and more.
Their perspective on research is based on multi-disciplinary teams working together to translate results to clinical practice. IGTP aims to reach excellence for health research to improve patient outcomes.
Since 2011, CALIXAR is expert in developing and implementing proprietary biochemical processes for production, stabilization, and characterization of challenging membrane targets for multiple applications (antibody/nanobody discovery by immunization or by phage/yeast display screening, small molecules screening, SBDD, identification of new MOAs...).
CALIXAR patented technology platform provides native, functional, and stable challenging membrane proteins in full length format (no mutations or any truncations) to secure the relevance/specificity of new leads discovery, and further to increase success in clinical stages. In addition, CALIXAR is extending its our own pipeline of membrane targets (GPCRs, ion channels, Transporters, viral/bacterial antigens…) of high relevance for Pharma/Biotech companies and Research Institutes.
